New weight loss injection BGM1812 enters early human testing

NCT ID NCT07224399

Recruiting now Disease control Sponsor: BrightGene Bio-Medical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called BGM1812, given as an injection under the skin, to see if it is safe and how it works in the body. The study involves 60 healthy adults who are overweight or obese. Researchers will measure weight changes and monitor for any side effects over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BGM1812 injection
What this could lead to: If successful, this could point toward a new treatment for weight management in people who are overweight or obese.
What could go wrong: This is an early Phase 1 trial with only 60 healthy participants, so safety and effectiveness are not yet proven. The drug may not lead to significant weight loss or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALHTY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALHTY OVERWEIGHT OR OBESITY

Contacts and locations

Locations

Pharmaron CPC, Inc
RECRUITING

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.